Nakae Shunsuke, Sasaki Hikaru, Hayashi Saeko, Hattori Natsuki, Kumon Masanobu, Nishiyama Yuya, Adachi Kazuhide, Nagahisa Shinya, Hayashi Takuro, Inamasu Joji, Abe Masato, Hasegawa Mitsuhiro, Hirose Yuichi
Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Department of Neurosurgery, Keio University, Tokyo, Japan.
PLoS One. 2015 Nov 11;10(11):e0142750. doi: 10.1371/journal.pone.0142750. eCollection 2015.
Genetic subgrouping of gliomas has been emphasized recently, particularly after the finding of isocitrate dehydrogenase 1 (IDH1) mutations. In a previous study, we investigated whole-chromosome copy number aberrations (CNAs) of gliomas and have described genetic subgrouping based on CNAs and IDH1 mutations. Subsequently, we classified gliomas using simple polymerase chain reaction (PCR)-based methods to improve the availability of genetic subgrouping. We selected IDH1/2 and TP53 as markers and analyzed 237 adult supratentorial gliomas using Sanger sequencing. Using these markers, we classified gliomas into three subgroups that were strongly associated with patient prognoses. These included IDH mutant gliomas without TP53 mutations, IDH mutant gliomas with TP53 mutations, and IDH wild-type gliomas. IDH mutant gliomas without TP53 mutations, which mostly corresponded to gliomas carrying 1p19q co-deletions, showed lower recurrence rates than the other 2 groups. In the other high-recurrence groups, the median progression-free survival (PFS) and overall survival (OS) of patients with IDH mutant gliomas with TP53 mutations were significantly longer than those of patients with IDH wild-type gliomas. Notably, most IDH mutant gliomas with TP53 mutations had at least one of the CNAs +7q, +8q, -9p, and -11p. Moreover, IDH mutant gliomas with at least one of these CNAs had a significantly worse prognosis than did other IDH mutant gliomas. PCR-based mutation analyses of IDH and TP53 were sufficient for simple genetic diagnosis of glioma that were strongly associated with prognosis of patients and enabled us to detect negative CNAs in IDH mutant gliomas.
最近,胶质瘤的基因亚组分类受到了重视,尤其是在发现异柠檬酸脱氢酶1(IDH1)突变之后。在之前的一项研究中,我们调查了胶质瘤的全染色体拷贝数畸变(CNA),并基于CNA和IDH1突变描述了基因亚组分类。随后,我们使用基于简单聚合酶链反应(PCR)的方法对胶质瘤进行分类,以提高基因亚组分类的可用性。我们选择IDH1/2和TP53作为标志物,并使用桑格测序法分析了237例成人幕上胶质瘤。使用这些标志物,我们将胶质瘤分为三个与患者预后密切相关的亚组。这些亚组包括无TP53突变的IDH突变型胶质瘤、有TP53突变的IDH突变型胶质瘤和IDH野生型胶质瘤。无TP53突变的IDH突变型胶质瘤大多对应携带1p19q共缺失的胶质瘤,其复发率低于其他两组。在其他高复发组中,有TP53突变的IDH突变型胶质瘤患者的无进展生存期(PFS)和总生存期(OS)的中位数明显长于IDH野生型胶质瘤患者。值得注意的是,大多数有TP53突变的IDH突变型胶质瘤至少有+7q、+8q、-9p和-11p中的一种CNA。此外,有这些CNA中至少一种的IDH突变型胶质瘤的预后明显比其他IDH突变型胶质瘤差。基于PCR的IDH和TP53突变分析足以对与患者预后密切相关的胶质瘤进行简单的基因诊断,并使我们能够在IDH突变型胶质瘤中检测到阴性CNA。